Acute “binge” cocaine increases mu-opioid receptor mRNA levels in areas of the rat mesolimbic mesocortical dopamine system

1999 ◽  
Vol 48 (1) ◽  
pp. 109-112 ◽  
Author(s):  
Vadim Yuferov ◽  
Yan Zhou ◽  
Rudolph Spangler ◽  
Christopher E Maggos ◽  
Ann Ho ◽  
...  
2002 ◽  
Vol 58 (3) ◽  
pp. 285-288 ◽  
Author(s):  
Eugene D Festa ◽  
Christine Cecala ◽  
Vanya Quinones-Jenab ◽  
Shirzad Jenab

1995 ◽  
Vol 33 (2) ◽  
pp. 351-355 ◽  
Author(s):  
Ellen M. Unterwald ◽  
Joshua M. Rubenfeld ◽  
Yasuo Imai ◽  
Jia-Bei Wang ◽  
George R. Uhl ◽  
...  

1997 ◽  
Vol 87 (5) ◽  
pp. 1127-1138 ◽  
Author(s):  
Elizabeth K. Gies ◽  
Dawn M. Peters ◽  
Carol R. Gelb ◽  
Kathleen M. Knag ◽  
Robert A. Peterfreund

Background The mu opioid receptor (MuOR) is a member of the superfamily of G protein-coupled receptors that mediates the analgesic actions of endogenous opioid peptides and the narcotic alkaloid derivatives of morphine. Activation and translocation of protein kinase C (PKC) by N-methyl-D-aspartate receptor stimulation correlates with resistance to opioid drugs in experimental states of neuropathic pain, but the cellular mechanisms of resistance have not been identified. One possibility is that PKC activation regulates MuOR mRNA expression and thus the ability to generate functional receptors. Using a human neuroblastoma cell line, the authors tested the hypothesis that phorbol ester activation of PKC regulates MuOR mRNA levels. Methods SH-SY5Y cells were maintained in a continuous monolayer culture and treated with phorbol esters or other agents before extraction of total cellular RNA. Slot-blot hybridization was used to measure the level of MuOR mRNA using 32P-labeled MuOR cDNA probes under high-stringency conditions. Autoradiograms were analyzed by scanning and densitometry. Results MuOR mRNA levels decreased in a dose- and time-dependent manner after tetradecanoyl phorbol acetate (TPA) was administered to activate PKC. The nadir, a level of approximately 50% of control, was at 2-8 h, followed by gradual recovery. The actions of TPA were blocked by pretreatment with the selective PKC inhibitor bisindolylmaleimide, but not by inhibition of protein synthesis with cycloheximide or anisomycin. The combination of TPA treatment and transcription inhibition with actinomycin D was associated with a transient increase in MuOR mRNA. Conclusions Mu opioid receptor mRNA levels are regulated by activation of PKC in a neuronal model. Protein kinase C effects which decrease MuOR mRNA levels appear largely independent of new protein synthesis, and cytotoxicity does not account for the findings. Plasticity of MuOR gene expression may contribute to variations in clinical responses to opioid analgesics in clinical states such as neuropathic pain.


1994 ◽  
Vol 54 (1) ◽  
pp. 307-308 ◽  
Author(s):  
E.M. Unterwald ◽  
J.M. Rubenfeld ◽  
R. Spangler ◽  
Y. Imai ◽  
J.B. Wang ◽  
...  

Analgesia ◽  
1995 ◽  
Vol 1 (4) ◽  
pp. 805-808 ◽  
Author(s):  
Ellen M. Unterwald ◽  
Joshua M. Rubenfeld ◽  
Jason Kreuter ◽  
Mary Jeanne Kreek

2006 ◽  
Vol 191 (1) ◽  
pp. 137-145 ◽  
Author(s):  
Yan Zhou ◽  
Jacob Bendor ◽  
Lauren Hofmann ◽  
Matthew Randesi ◽  
Ann Ho ◽  
...  

In this study, we investigated the effects of acute morphine administration, chronic intermittent escalating-dose morphine administration and spontaneous withdrawal from chronic morphine on mRNA levels of mu opioid receptor (MOP-r), and the opioid peptides pro-opiomelanocortin (POMC) and preprodynorphin (ppDyn) in several key brain regions of the rat, associated with drug reward and motivated behaviors: lateral hypothalamus (lat.hyp), nucleus accumbens (NAc) core, amygdala, and caudate–putamen (CPu). There was no effect on MOP-r mRNA levels in these brain regions 30 min after either a single injection of morphine (10 mg/kg, i.p.) or chronic intermittent escalating-dose morphine (from 7.5 mg/kg per day on day 1 up to 120 mg/kg per day on day 10). Activation of the stress-responsive hypothalamic–pituitary–adrenal axis by 12 h withdrawal from chronic morphine was confirmed; both POMC mRNA levels in the anterior pituitary and plasma adrenocorticotropic hormone levels were significantly elevated. Under this withdrawal-related stress condition, there was an increase in MOP-r mRNA levels in the lat.hyp, NAc core, and CPu. Recent studies have demonstrated a novel role for the lat.hyp orexin (or hypocretin) activation in both drug-related positive rewarding, and withdrawal effects. Around 50% of lat.hyp orexin neurons express MOP-r. Therefore, we also examined the levels of lat.hyp orexin mRNA, and found them increased in morphine withdrawal, whereas there was no change in levels of the lat.hyp ppDyn mRNA, a gene coexpressed with the lat.hyp orexin. Our results show that there is an increase in MOP-r gene expression in a region-specific manner during morphine withdrawal, and support the hypothesis that increased lat.hyp orexin activity plays a role in morphine-withdrawal-related behaviors.


Sign in / Sign up

Export Citation Format

Share Document